|Year : 2020 | Volume
| Issue : 1 | Page : 24-30
An open-label, single-arm pilot study of EUS-guided brachytherapy with phosphorus-32 microparticles in combination with gemcitabine +/- nab-paclitaxel in unresectable locally advanced pancreatic cancer (OncoPaC-1): Technical details and study protocol
Manoop S Bhutani1, Jason B Klapman2, Richard Tuli3, Ghassan El-Haddad4, Sarah Hoffe5, Franklin C. L. Wong6, Beth Chasen6, David R Fogelman7, Simon K Lo8, Nicholas N Nissen9, Andrew E Hendifar10, Gauri Varadhachary7, Matthew H. G. Katz11, William D Erwin12, Eugene J Koay13, Eric P Tamm14, Ben S Singh1, Rutika Mehta2, Robert A Wolff7, Ashish Soman15, Irina M Cazacu1, Joseph M Herman13
1 Department of Gastroenterology, Hepatology and Nutrition, Houston, TX, USA
2 Department of Gastrointestinal Oncology, Moffitt Cancer Center, Tampa, FL, USA
3 Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA
4 Department of Diagnostic Imaging and Interventional Radiology, Moffitt Cancer Center, Tampa, FL, USA
5 Department of Radiation Oncology, Moffitt Cancer Center, Tampa, FL, USA
6 Department of Nuclear Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
7 Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
8 Division of Digestive and Liver Diseases, Cedars Sinai Medical Center, Los Angeles, CA, USA
9 Department of Surgery, Cedars Sinai Medical Center, Los Angeles, CA, USA
10 Department of Hematology/Oncology, Cedars Sinai Medical Center, Los Angeles, CA, USA
11 Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
12 Department of Imaging Physics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
13 Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
14 Department of Diagnostic Radiology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
15 Department of OncoSil Medical Ltd., Sydney, Australia
|Date of Submission||23-Apr-2019|
|Date of Acceptance||24-Jun-2019|
|Date of Web Publication||30-Oct-2019|
Joseph M Herman
Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, T. Boone Pickens Academic Tower (FCT6.6080), 1515 Holcombe Blvd., Unit 1442, Houston, Texas 77030
Manoop S Bhutani
Department of Gastroenterology, Hepatology and Nutrition, The University of Texas Anderson Cancer Center, 1515 Holcombe Blvd., Houston 77030-4009, Texas
Source of Support: None, Conflict of Interest: None
Current treatment options for patients with unresectable locally advanced pancreatic cancer (LAPC) include chemotherapy alone or followed by chemoradiation or stereotactic body radiotherapy. However, the prognosis for these patients remains poor, with a median overall survival <12 months. Therefore, novel treatment options are needed. Currently, there is no brachytherapy device approved for pancreatic cancer treatment. Hereby, we present the protocol of a prospective, multicenter, interventional, open-label, single-arm pilot study (OncoPac-1, Clinicaltrial.gov-NCT03076216) aiming to determine the safety and efficacy of Phosphorus-32 when implanted directly into pancreatic tumors using EUS guidance, for patients with unresectable LAPC undergoing chemotherapy (gemcitabine ± nab-paclitaxel).
Keywords: Brachytherapy, chemotherapy, endoscopy, EUS, fine needle injection, intratumoral therapy, neoplasia, pancreatic cancer, phosphorus-32, radiotherapy
|How to cite this article:|
Bhutani MS, Klapman JB, Tuli R, El-Haddad G, Hoffe S, Wong FC, Chasen B, Fogelman DR, Lo SK, Nissen NN, Hendifar AE, Varadhachary G, Katz MH, Erwin WD, Koay EJ, Tamm EP, Singh BS, Mehta R, Wolff RA, Soman A, Cazacu IM, Herman JM. An open-label, single-arm pilot study of EUS-guided brachytherapy with phosphorus-32 microparticles in combination with gemcitabine +/- nab-paclitaxel in unresectable locally advanced pancreatic cancer (OncoPaC-1): Technical details and study protocol. Endosc Ultrasound 2020;9:24-30
|How to cite this URL:|
Bhutani MS, Klapman JB, Tuli R, El-Haddad G, Hoffe S, Wong FC, Chasen B, Fogelman DR, Lo SK, Nissen NN, Hendifar AE, Varadhachary G, Katz MH, Erwin WD, Koay EJ, Tamm EP, Singh BS, Mehta R, Wolff RA, Soman A, Cazacu IM, Herman JM. An open-label, single-arm pilot study of EUS-guided brachytherapy with phosphorus-32 microparticles in combination with gemcitabine +/- nab-paclitaxel in unresectable locally advanced pancreatic cancer (OncoPaC-1): Technical details and study protocol. Endosc Ultrasound [serial online] 2020 [cited 2021 Jan 16];9:24-30. Available from: http://www.eusjournal.com/text.asp?2020/9/1/24/270055
| Introduction|| |
Pancreatic ductal adenocarcinoma is associated with a poor prognosis and has an increasing impact on cancer-related mortality worldwide. Pancreatic cancer is projected to become the second leading cause of cancer-related deaths by 2030.
There is no uniform consensus regarding standard of care treatment of unresectable locally advanced pancreatic cancer (LAPC). The current treatment options include chemotherapy alone or chemotherapy followed by chemoradiotherapy or stereotactic body radiation therapy (SBRT). Conventional radiotherapy (CRT) over 5–6 weeks has been used to treat patients with advanced disease and is usually given concurrently with gemcitabine or fluoropyrimidine-based chemotherapy. However, CRT is limited by the amount of radiation that can be delivered to the gastrointestinal (GI) tract due to side effects. SBRT uses high doses of RT that can be delivered in only 1 week and offers a similar local control as CRT while sparing surrounding normal tissues. While these advances have led to improved tumor control, downstaging remains limited and thus the likelihood of surgery is low. In addition, the current doses of radiation have resulted in pathological complete remission (pCR) rates of only 10%, suggesting that higher radiotherapy doses are needed for achieving better pCR rates.
Brachytherapy is a form of radiotherapy where radioactive seeds, microparticles, or liquids are placed directly into or adjacent to the tumor. This technique is currently used in the treatment of prostate, cervical, and breast cancer, but also in other malignancies (lung, head and neck, and liver cancer).,,, With brachytherapy, the target tissue is exposed to a steady emission of low-energy gamma, X-rays, or beta particles, which leads to localized tissue injury and tumor ablation. Brachytherapy can deliver a much higher dose of radiation to the tumor when compared to external beam radiation therapy where radiation beams need to traverse normal structures to treat the tumor, thus resulting in collateral toxicity and damage to normal tissue.
There is currently no brachytherapy device approved for the treatment of pancreatic cancer. However, there is evidence to suggest that brachytherapy can deliver a higher dose of radiation and has the potential to offer local control and to provide palliative benefits in patients with LAPC who have few treatment options and whose prognosis is otherwise poor.,,,, Trials and commercialization of brachytherapy treatments and devices utilizing radioisotopes of phosphorus-32 (P-32), iodine, gold, iridium, and yttrium have been undertaken.,,,,, However, none of these radioactive agents has entered routine clinical practice.
Various techniques for delivery of local radiation have been reported. Initially, intraoperative brachytherapy was used for patients who received palliative surgery. Other methods to place radioactive seeds within the tumor include computed tomography (CT) or ultrasound-guided procedures. EUS has evolved as an interventional procedure, and multiple agents can be delivered under EUS guidance. Thus, EUS is not only useful in the delivery of fiducial markers for guiding external radiotherapy but can also be employed to deliver radioactive seeds into solid tumors. Compared with percutaneous implantation using CT or abdominal ultrasound, EUS provides a clear real-time image, with a more direct puncture pathway.
Conversion to resectability is one of the goals of the treatment in LAPC, although actual downstaging of tumors with the current treatment strategies is very uncommon. EUS-guided brachytherapy in conjunction with chemotherapy may increase the proportion of LAPC patients undergoing surgery or result in more durable local control than conventional treatments.
| Rationale And Objective|| |
P-32 has been previously investigated in combination with gemcitabine monotherapy in 23 patients with LAPC and metastatic disease in two phase II clinical studies which demonstrated acceptable tolerability and safety profile. One of the studies was presented as an abstract and the other one is on file with the company. Efficacy data showed potential with evidence of a target tumor response rate of 23% and a target disease control rate of 82%. These studies suggested that EUS-guided implantation of P-32 is a feasible method of delivery.
The OncoPac-1 multicenter clinical trial is further investigating the safety of P-32 radiolabeled microparticles (OncoSil™) when implanted directly into pancreatic tumors using EUS for patients with unresectable LAPC undergoing chemotherapy (clinicaltrials.gov, NCT03076216). This is the first US experience with P-32. The implanted activity is intended to deliver an average radiation absorbed dose of 100 Gy (±20%) within the tumor. The dose of 100 Gy proposed in the present OncoPac-1 study has been selected as it has shown to be safe and well tolerated in a previous phase II pancreatic cancer clinical trial (DB2-201) that encompassed the largest pool of patients to date (17 patients).
In the OncoPac-1 trial, the eligible patients receive either gemcitabine or gemcitabine + nab-paclitaxel chemotherapy plus P-32 brachytherapy.
The primary endpoint is safety and tolerability of P-32 administered in combination with chemotherapy. The common terminology criteria for adverse events (AEs) are being used to grade and report AEs. The following secondary endpoints are also being assessed: feasibility, local progression-free survival, progression-free survival, overall survival, pain scores, impaired function, and volumetric target tumor changes [Table 1].
| Study Design|| |
OncoPac-1 is a prospective, multicenter, interventional, open-label, single-arm pilot study aiming to determine the safety of P-32 when implanted directly into pancreatic tumors using EUS guidance, for patients with unresectable LAPC undergoing chemotherapy (gemcitabine ± nab-paclitaxel) [Figure 1]. This clinical trial is being conducted at 3 sites in the United States.
Patients are enrolled into the study only if they meet all of the required criteria at screening. The key eligibility criteria for this study are as follows: histological-/cytological-proven pancreatic adenocarcinoma; unresectable LAPC, without distant metastasis; target tumor diameter 2–6 cm, Eastern Cooperative Oncology Group performance Status 0–1; and naïve treatment patients [Table 2].
The appropriate chemotherapy regimen is determined by the treating oncologist on an individual subject basis and administered in accordance with the manufacturer's approved intended purpose, indications for use, and conditions of approval. Chemotherapy commences at a maximum of 14 days postenrollment. The EUS-guided implantation of P-32 microparticles occurs during the 4th or 5th week of the 1st cycle of chemotherapy. Following implantation, the prescribed chemotherapy regimen is resumed. Due to the potential of chemotherapy agents to be radiosensitizing, at least 48 h must elapse either side of the P-32 implantations to the start/finish of the chemotherapy infusion.
To assess the intratumoral and potential extratumoral distribution of microparticles, bremsstrahlung whole-body planar plus single-bed single photon emission CT/(SPECT)/CT imaging is performed within 4 h postimplantation and repeated 7 days after.
Follow-up CT scans are repeated every 8 weeks to assess volumetric tumor response. A medical review of all AEs reported by patients will continue until 104 weeks post enrollment of the last patient.
| Methods|| |
OncoSil is an investigational brachytherapy device containing P-32-radiolabeled microparticles uniformly suspended within a diluent. The P-32 microparticles have been designed to deliver a localized distribution of beta-radiation within the target tumor. The radiation from these particles causes direct damage to cancer cell DNA, which renders them incapable of further cell division and proliferation. Through this mechanism, P-32 is able to stop cancer cells from multiplying which leads to tumor shrinkage. The diluent is a viscous suspension that serves as a carrier to facilitate intratumoral implantation of the microparticles.
The microparticles are manufactured in Germany, and P-32 is produced via neutron activation of the microparticles in a nuclear reactor. The activity for each patient is dispensed, sterilized, and packaged for shipment to the study site. Twenty-eight days between placing an order and availability of P-32 at the study site is required.
Dose calculation and preparation
The baseline target tumor volume is estimated from the screening/baseline CT scan and is used to calculate the volume of diluent containing the P-32 to be implanted. The P-32 microparticles and diluent are combined in accordance with a predefined suspension preparation protocol.
A single dose is implanted into the tumor using the final suspension of P-32 with a radioactivity concentration of 6.6 MBq/mL (the radioactivity concentration required, with an implanted volume/tumor volume of 8%, to deliver 100 Gy to the tumor mass).
The two equations shown below are used to calculate actual volume of P-32 dispensed and then implanted:
Activity to be implanted (MBq) = Volume to be implanted (mL) × 6.6
The required volume is drawn up into a 3 or 5 mL syringe within a beta shield which is placed in a lead transport box. The dispensed dose must be used within 24 h of preparation and stored between 15°C and 25°C. The nuclear medicine technologist or a radiopharmacist dispenses the dose and transports it to the endoscopy suite.
An overview of the P-32 implantation is shown in [Figure 2].
Radiation safety is an important consideration in the use of P-32 brachytherapy, from the receipt of the radioactive material, its preparation and administration to the patient, to the release of the patient from the treatment facility. The beta emissions from P-32 can present an inhalation, skin, and eye dose hazard; thus, appropriate personnel protective equipment must be used. A radiation monitor suitable for detecting P-32 is used to assess operational areas for contaminations. A special decontamination kit must be available for immediate use in case of any spills of P-32.
The endoscopy suite is carefully prepared before the procedure. Spill tray lined with plastic-backed absorbent material is used to cover the floor. The room is equipped with clinical radioactive waste disposal bags, protective clothing, monitor suitable for detecting P-32, radiation spill kit, and appropriate personnel dosimetry for handling P-32.
Periprocedural intravenous prophylactic antibiotic treatment is administered (on the day of the procedure and for 2 days after).
The target pancreatic lesion is identified using EUS. A 22 gauge FNA needle is loaded through the biopsy channel of the echoendoscope and slowly advanced into the target pancreatic tumor. Once the FNA needle is in a satisfactory position within the tumor and safe insertion window is identified, the stylet is removed and the syringe with P-32 is attached to the FNA needle.
P-32 is injected in the center of the tumor using a needle tracking technique by pulling the needle back when the injection becomes difficult. A radiation oncologist or a nuclear medicine physician slowly depresses the plunger of the syringe in beta shield to implant P-32. The injection is seen as an echogenic blush within the tumor [Figure 3]. Saline is used to flush the P-32 remaining in the needle into the tumor, and then, the needle is withdrawn back into the sheath. Additional flush with saline is done with the sheath within the GI lumen. The sheath is not fully retracted into the echoendoscope to decrease the risk of scope contamination. The echoendoscope is gently withdrawn out of the patient.
|Figure 3: EUS showing an 18 mm × 13 mm hypoechoic irregular tumor in pancreatic body. The hypoechoic tumor after phosphorus-32 injection is mostly replaced by the hyperechoic “cloud”|
Click here to view
Following the procedure, all materials are sterilized and disposed of following radiation safety guidelines and under the supervision of the institutional Radiation Safety Department.
After completion of the implantation, the syringe containing any residual P-32 suspension is recapped, placed into the lead transport box, and transferred to the Nuclear Medicine Department/Radiopharmacy for measurement and then decay.
The scope tip is held over a clinical waste bag and rinsed with 50 mL water. The echoendoscope and the staff are checked for any radioactive contamination using the radiation monitor. The echoendoscope is washed and sterilized using the standard methods for cleaning the equipment at the study site.
Following implantation, it is recommended that patients be observed for 4 h (with regular observations of consciousness and vital signs as clinically indicated) and if stable and pain-free, they may be discharged the same day.
Assessment of intratumoral localization of phosphorus-32
Whole-body planar plus single-bed SPECT/CT imaging of P-32 bremsstrahlung radiation is performed within 4 h postimplantation and again at 7 days, to assess the intratumoral and any potential extratumoral distribution of the P-32 microparticles, as well as, quantify whether or not the entirety of the P-32 radioactivity remained at the implantation site [Figure 4].
|Figure 4: Single photon emission computed tomography-computed tomography bremsstrahlung imaging showing excellent intratumoral retention of phosphorus-32 within the pancreatic body at 4-h postimplantation (a) and at 7-day postimplantation (b)|
Click here to view
The ratio of activity at 7 days to that within 4 h at the implantation site should be consistent with radioactive decay of P-32 only, indicative of no microparticles having migrated elsewhere.
The treatment follow-up period consists of investigational visits which occur weekly from visit 1 (Day 0) until week 12, then 4 weeks later at week 16, and then at 8-weekly intervals until study participants reach documented progression of disease criteria for both local progression-free survival and progression-free survival which marks the end of study participation.
Centrally read CT scans are acquired every 8 weeks to assess response defined as complete response, partial response, and stable disease according to Response Evaluation Criteria in Solid Tumor 1.1 criteria.
Telephone contact every 8 weeks is used to monitor device or late radiation-related AEs, and oncology treatments/procedures are administered for up to 12 months post P-32 implantation. Overall survival is assessed by medical record reviews conducted every 8 weeks and/or telephone contact until subject death, or until 104 weeks after the last subject was enrolled.
| Eus-Guided Phosphorus-32 Implantation-Early Results|| |
Thus far, a total of 9 patients with a median age of 71 years (range 57–87) have been enrolled in the study at 3 sites in the US. The EUS procedure was technically feasible, and P-32 was successfully implanted in all cases. No serious immediate procedure-related AEs were reported. The clinical trial is ongoing, and additional safety and efficacy data will be presented at the completion of the study.
Financial support and sponsorship
OncoPac-1 Study is funded by OncoSil Medical Ltd., Sydney, Australia.
Conflicts of interest
OncoPac-1 Study is funded by OncoSil Medical Ltd., Sydney, Australia. Dr. Bhutani is the recipient of research support from Oncosil, Galera, Augmenix, and Silenseed. Dr. Tamm is associated with General Electric. Dr. Herman is the recipient of research support from Oncosil, Galera, Aduro, and Augmenix, and is a consultant for BTG, AbbVie, Celgene, AstraZeneca, BMS, Varian, and Boston Scientific. The other authors disclosed no financial relationships relevant to this publication.
| References|| |
Aier I, Semwal R, Sharma A, et al
. A systematic assessment of statistics, risk factors, and underlying features involved in pancreatic cancer. Cancer Epidemiol
Cardenes HR, Chiorean EG, Dewitt J, et al
. Locally advanced pancreatic cancer: Current therapeutic approach. Oncologist
Herman JM, Chang DT, Goodman KA, et al.
Phase 2 multi-institutional trial evaluating gemcitabine and stereotactic body radiotherapy for patients with locally advanced unresectable pancreatic adenocarcinoma. Cancer
Mellon EA, Jin WH, Frakes JM, et al.
Predictors and survival for pathologic tumor response grade in borderline resectable and locally advanced pancreatic cancer treated with induction chemotherapy and neoadjuvant stereotactic body radiotherapy. Acta Oncol
Sakurai H, Mitsuhashi N, Harashima K, et al.
CT-fluoroscopy guided interstitial brachytherapy with image-based treatment planning for unresectable locally recurrent rectal carcinoma. Brachytherapy
Merrick GS, Butler WM, Wallner KE, et al
. Permanent interstitial brachytherapy for clinically organ-confined high-grade prostate cancer with a pretreatment PSA<20 ng/mL. Am J Clin Oncol
Viola A, Major T, Julow J. The importance of postoperative CT image fusion verification of stereotactic interstitial irradiation for brain tumors. Int J Radiat Oncol Biol Phys
Viswanathan AN, Thomadsen B; American Brachytherapy Society Cervical Cancer Recommendations Committee, American Brachytherapy Society. American Brachytherapy Society consensus guidelines for locally advanced carcinoma of the cervix. Part I: General principles. Brachytherapy
Upcott H. VII. Tumors of the ampulla of vater: With a report of two cases. Ann Surg
Handley WS. Pancreatic cancer and its treatment by implanted radium. Ann Surg
Shipley WU, Nardi GL, Cohen AM, et al
. Iodine-125 implant and external beam irradiation in patients with localized pancreatic carcinoma: A comparative study to surgical resection. Cancer
Westlin JE, Andersson-Forsman C, Garske U, et al.
Objective responses after fractionated infusional brachytherapy of unresectable pancreatic adenocarcinomas. Cancer
DeNittis AS, Stambaugh MD, Lang P, et al.
Complete remission of nonresectable pancreatic cancer after infusional colloidal phosphorus-32 brachytherapy, external beam radiation therapy, and 5-fluorouracil: A preliminary report. Am J Clin Oncol
Peretz T, Nori D, Hilaris B, et al.
Treatment of primary unresectable carcinoma of the pancreas with I-125 implantation. Int J Radiat Oncol Biol Phys
Borgelt B. Radiation therapy with either gold grain implant or neutron beam for unresectable adenocarcinoma of the pancreas. Pancreatic Cancer New Directions in Therapeutic Management. New York: Masson Publishing; 1981. p. 55-62.
Order SE, Siegel JA, Principato R, et al.
Preliminary experience of infusional brachytherapy using colloidal 32P. Ann Acad Med Singapore
Rosemurgy A, Luzardo G, Cooper J, et al.
32P as an adjunct to standard therapy for locally advanced unresectable pancreatic cancer: A randomized trial. J Gastrointest Surg
Goertz SR, Ali MM, Parker GA. Local management of pancreatic carcinoma: Iodine-125 implantation. Clin Oncol (R Coll Radiol)
Du YQ, Li ZS, Jin ZD. Endoscope-assisted brachytherapy for pancreatic cancer: From tumor killing to pain relief and drainage. J Interv Gastroenterol
Cazacu IM, Luzuriaga Chavez AA, et al
. A quarter century of EUS-FNA: Progress, milestones, and future directions. Endosc Ultrasound
Ross PJ, Meenan J, O'Doherty M, et al
. Novel delivery via endoscopic ultrasound of a 32P brachytherapy device in addition to gemcitabine (G) in advanced pancreatic cancer. Abstract book of ASCO Gastrointestinal Cancers Symposium, January 26-28, American Society for Clinical Oncology's. Abstract no. 205.
[Figure 1], [Figure 2], [Figure 3], [Figure 4]
[Table 1], [Table 2]
|This article has been cited by|
||Investigation of silicon nanoparticles produced by centrifuge chemical vapor deposition for applications in therapy and diagnostics
| ||Dave Lumen,Shiqi Wang,Ermei Mäkilä,Surachet Imlimthan,Mirkka Sarparanta,Alexandra Correia,Christina Westerveld Haug,Jouni Hirvonen,Hélder A. Santos,Anu J. Airaksinen,Werner Filtvedt,Jarno Salonen |
| ||European Journal of Pharmaceutics and Biopharmaceutics. 2020; |
|[Pubmed] | [DOI]|
||Review of brachytherapy complications – Upper gastrointestinal tract
| ||Michael R. Folkert,Sujana Gottumukkala,Nhu Tram Nguyen,Amandeep Taggar,Ranjan Kumar Sur |
| ||Brachytherapy. 2020; |
|[Pubmed] | [DOI]|